Palisade Bio Reports Third Quarter 2026 Financial Results and Advances PALI-2108 Phase 2 Clinical Development Programs
Globe Newswire•10/11/2026•16:25 ET
0
Key Highlights
- ➤ASCENTRA-UC first patient dosed October 27, 2026; topline results expected Q4 2027
- ➤FDA cleared ASCENTRA-CD Phase 2a IND; enrollment targeted for Q1 2027
- ➤$113.6 million cash and equivalents supports operations through key Phase 2 readouts
- ➤Third-quarter net loss $14.6 million, or $0.07 per share
- ➤PALI-2108 showed endoscopic improvement within two weeks in five-patient Crohn’s cohort
Expert Statements
JD Finley, Chief Executive Officer of Palisade Bio
“ASCENTRA-UC is now underway, and our focus is on driving enrollment and executing the study to deliver topline results in the fourth quarter of 2027. With nearly all planned U.S. sites activated, we are expanding our global clinical footprint to build on that progress.”
JD Finley, Chief Executive Officer of Palisade Bio
“Our strong financial position supports execution across both programs as we work to establish PALI-2108’s potential as a differentiated, once-daily oral treatment for patients living with IBD.”
Mitch Jones, M.D., Ph.D., President and Chief Medical Officer of Palisade Bio
“Now that ASCENTRA-UC is underway, our priority is to maintain enrollment momentum and deliver the clinical data needed to establish PALI-2108’s potential in ulcerative colitis.”
Mitch Jones, M.D., Ph.D., President and Chief Medical Officer of Palisade Bio
“We expect the results to provide a clearer understanding of its ability to induce remission, reduce intestinal inflammation and support sustained disease control.”
Mitch Jones, M.D., Ph.D., President and Chief Medical Officer of Palisade Bio
“In Crohn’s disease, we are focused on preparing ASCENTRA-CD for initiation of enrollment in the first quarter of 2027.”
Mitch Jones, M.D., Ph.D., President and Chief Medical Officer of Palisade Bio
“We are pursuing these programs with the goal of developing a treatment that, if approved, could offer patients an effective, well-tolerated treatment that fits into daily life through once-daily oral dosing.”
First Patient Dosed in Global Phase 2b ASCENTRA-UC Trial; Topline Results Expected in Q4 2027
FDA Clearance Received for Phase 2a ASCENTRA-CD Trial; Initiation of Enrollment Targeted for Q1 2027
Get started
Create a free account to read the full story.